Antibacterial discovery and development—the failure of success?
- 1 December 2006
- journal article
- review article
- Published by Springer Nature in Nature Biotechnology
- Vol. 24 (12) , 1497-1503
- https://doi.org/10.1038/nbt1206-1497
Abstract
A combination of approaches and compounds—many of which failed to yield immediate results in the past—will ultimately prove invaluable to the drug industry in the ongoing battle against infectious disease.Keywords
This publication has 68 references indexed in Scilit:
- Biochemical Characterization of the Interactions of the Novel Pleuromutilin Derivative Retapamulin with Bacterial RibosomesAntimicrobial Agents and Chemotherapy, 2006
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- The worldwide emergence of plasmid-mediated quinolone resistanceThe Lancet Infectious Diseases, 2006
- An array of Escherichia coli clones over-expressing essential proteins: A new strategy of identifying cellular targets of potent antibacterial compoundsBiochemical and Biophysical Research Communications, 2006
- Are Broad-Spectrum Fluoroquinolones More Likely To Cause Clostridium difficile -Associated Disease?Antimicrobial Agents and Chemotherapy, 2006
- Methicillin-ResistantS. aureusInfections among Patients in the Emergency DepartmentNew England Journal of Medicine, 2006
- Dissecting virulence pathways of Mycobacterium tuberculosis through protein–protein associationProceedings of the National Academy of Sciences, 2006
- Antipneumococcal Activity of DW-224a, a New Quinolone, Compared to Those of Eight Other AgentsAntimicrobial Agents and Chemotherapy, 2006
- Sampling the Antibiotic ResistomeScience, 2006
- The Future of the QuinolonesDrugs, 1993